Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Ryotaro
Contact Ryotaro, search articles and posts on X, monitor coverage, and track replies from one place.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
A Correction on Tumor Akkermansia muciniphila predicts clinical response to immune checkpoint inhibitors in non-small-cell lung cancer patients with low PD-L1 expression By Shimizu T, Ohkuma R, Homma M, Nakayama S, Sasaki Y, Muto S, Ieguchi K, Watanabe M, Taguchi A, Takayanagi D, Wada Y, Horiike A, Kubota Y, Ariizumi H, Shimokawa M, Hirasawa Y, Ishiguro T, Suzuki R, Iriguchi N, Mura E, Yoshimura K, Tsuji M, Kiuchi Y, Suzuki H and Yamochi T (2025) Front. Immunol. 16:1528594.
Abstract Combining immunotherapy with chemoradiation is effective in locally advanced cervical cancer. However, the impact of induction combination immunotherapy on immune modulation and treatment response is poorly understood. In this phase II trial (NCT04256213), 40 females with locally advanced cervical carcinoma received one cycle of nivolumab-plus-ipilimumab immunotherapy before standard chemoradiation, followed by maintenance nivolumab.
1 Introduction The efficacy of immune checkpoint inhibitors (ICIs) has been linked to the gut microbiota. Landmark studies in mice and humans have demonstrated that certain commensal bacteria could enhance antitumor immunity and improve ICI response (1, 2). Conversely, microbiome disruption (e.g., by antibiotics) before or during ICI therapy is associated with significantly worse survival outcomes in studies from our institute and others (3, 4).
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
